Publishing new research findings certainly has its benefits, but how physicians use that information and their personal experience in clinical practice can prove to be more insightful. In this article, we feature three physicians who participated in the rapid-fire Q&A “60 Tips in 60 Minutes” from the Winter Clinical Dermatology Conference held in January in Hawaii.
The combination of encorafenib plus binimetinib significantly improved overall survival versus vemurafenib in patients with BRAF-mutant melanoma, updated results of the randomized, phase three COLUMBUS trial show.
Researchers reporting at the American Society of Clinical Oncology annual meeting on June 4 presented a study in which they compared the seventh and eighth editions of the American Joint Committee on Cancer melanoma staging systems. The eighth edition differentiates melanoma survival slightly worse than the previous edition.
Pembrolizumab has antitumor activity that is durable long after treatment is stopped in patients with advanced melanoma, researchers reported at the 2018 annual meeting of the American Society of Clinical Oncology (ASCO) on June 4.
In April we reviewed the first five tips to help boost your resilience and well being in 2018. Below are the final five in the second part of this two-part article.
Acne may primarily be a genetic condition, but one that is compounded by environmental and social influences, shows a twins study published in the Journal of Drugs in Dermatology (JDD). This study is among a select group of studies featured in this month's acne supplement.
In a comparison of the performance between physician assistants and dermatologists, physician assistants may have lower diagnostic accuracy for melanoma than dermatologists, suggests a study published in JAMA Dermatology. The AAPA and SDPA question the use of the NNB ratio to determine diagnostic accuracy.
Pilot study tests whether PDL prior to surgical excision can prevent scarring
Publishing new research findings has its benefits, but how physicians use that information and their personal experience in clinical practice can prove to be more insightful. In this table on page 98 of Dermatology Times June issue, we feature insights from three physicians who participated in the rapid-fire Q&A “60 Tips in 60 Minutes” from this year's Winter Clinical Dermatology Conference.
UCB’s Cimzia (certolizumab pegol) was recommended for approval by the European Committee for Medicinal Products (CHMP) for the treatment of adult patients with moderate-to-severe plaque psoriasis.